Felix Theeuwes, D.Sc. is Chairman, co-founder, and Distinguished Scientist at DURECT Corporation, established in July of 1998 as a spinout from ALZA Corporation to focus on the development of pharmaceutical systems and products to treat chronic debilitating diseases and enabling biotechnology drugs.
Dr. Theeuwes was with ALZA Corporation from 1970 until June 1999 holding positions directing research, technology development, and product development for a variety of controlled drug delivery systems. His work led to the product introduction of the ALZET mini osmotic pump series for animal research, and the OROS systems series of products. He directed research in transdermal research and development, initiated the electrotransport/iontophoresis program, and initiated the DUROS osmotic implant program. He holds more than 210 U.S. patents covering these systems and published more than 80 articles and book chapters.
In 1980 Dr. Theeuwes was named Inventor of the Year by the Peninsula Patent Law Association. In 1983 he was the recipient of the Award for the Advancement of Industrial Pharmacy. He was the Busse Lecturer at the University of Wisconsin in 1981, and in 1985 the Third Annual Sidney Riegelman Lecturer at the University of California, San Francisco. He is a Fellow of the American Association of Pharmaceutical Scientists. In 1993 he became the first recipient of ALZA Corporation's Founder's Award.
In 1993 Dr. Theeuwes completed the Stanford Executive Program (SEP). He received his undergraduate and graduate education in physics at the University of Leuven (Louvain), Belgium, with a D.Sc. degree in 1966. From 1966 to 1970 he served as a post-doctoral fellow and visiting research assistant professor in the Department of Chemistry, University of Kansas.
James E. Brown, D.V.M. co-founded DURECT in February 1998 and has served as President, Chief Executive Officer and a Director since June 1998.
He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995, Director of Joint Ventures for Discovery Research from April 1992 to May 1995, and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992.
Dr. Brown holds a B.A. from San Jose State University and a D.V.M. (Doctor of Veterinary Medicine) from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology.
Michael H. Arenberg was appointed Chief Financial Officer effective October 2018. Mr. Arenberg has been with DURECT since 1999, most recently serving as Senior Vice President, Corporate and Business Development, where he negotiated and closed over 50 collaborations, including several important in-licensing transactions. Mr. Arenberg earned his undergraduate degree from the University of Colorado, his law degree from the University of Denver, and his MBA from the Leavy School of Business at Santa Clara University.
Judy Joice, Senior Vice President, Operations and Corporate Quality Assurance, joined DURECT in 2007 and has over 25 years experience in the pharmaceutical industry with such companies as Nektar Therapeutics, Oread and Syntex Research. During her career, Ms. Joice has gained broad experience in developing, implementing and managing all aspects of company-wide quality systems and compliance functions, ranging from drug development through commercial manufacturing. Ms. Joice has a B.S. in Chemistry from California State University.
WeiQi Lin, M.D., Ph.D. joined DURECT in 2008 and is Senior Vice President, Research and Development, R&D Business Development & Principal Scientist. Dr. Lin began her career at ALZA, where she worked for 10 years, developing an extensive knowledge of drug delivery systems which has proven invaluable to her role at DURECT. While at ALZA, she was a member of a team which was responsible for product pipeline selection and evaluation. After ALZA and prior to joining DURECT, she was a co-founder of a company and acted as a consultant. As a result, she has over 17 years of experience in industry. After graduation, she worked as a lecturer for 4 years at both Shanghai Medical University and Beijing Medical University. She received her M.D. from Shanghai Medical University, was a visiting scholar at the Medical College of Virginia and received her Ph.D. Pharm/Tox from the Medical College of Virginia.
Dr. Ellis joined DURECT in November 2011 and has over 45 years of experience in the pharmaceutical industry with companies such as Syntex, ALZA Corporation, Neurex Corporation, Elan Pharmaceuticals, ARYx Therapeutics and Relypsa. During his career, Dr. Ellis has been involved in 5 NDA submissions and approvals, and has extensive experience in clinical trial design, execution and reporting. Dr. Ellis has a B.S. in Chemistry from Colorado State University, a Ph.D. in Organic Chemistry from the University of California, Berkeley, and an M.D. from the University of California, San Francisco.
John W. Gibson, M.S., Vice President, Birmingham Operations and Principal Scientist, has over 30 years of pharmaceutical product development experience involving biodegradable excipients and injectable, long-acting formulations. Mr. Gibson joined DURECT in 2001 as Executive Director of Product Development and assumed management responsiblity for DURECT’s Birmingham operations in 2005. Prior to joining DURECT, from 1974 through 2000, Mr. Gibson held a variety of technical and management positions with Southern Biosystems, Eastman Chemical Company, Eli Lilly and Company, and Southern Research Institute. Mr. Gibson received his B.S. and M.S. in Chemistry from the University of Alabama at Birmingham. He has numerous scientific publications and is the inventor of several U.S. and foreign patents.
Steve Helmer joined DURECT in 2010 and is Vice President, Chief Patent Counsel. Mr. Helmer has over 17 years of experience as a patent attorney. After law school, he worked at the U.S. Patent and Trademark Office for 2 years, and then was a patent attorney at various law firms for the next 8 years. At that point, Steve switched over to the corporate side as patent counsel for Nektar Therapeutics for 5 years, followed by one year at Life Technologies prior to joining DURECT. Steve received his J.D. from the University of Minnesota Law School (cum laude) and received an M.S. in Biotechnology from Johns Hopkins University, and a B.S. in Chemical Engineering from Michigan Technological University (magna cum laude).
Robert M. Janosky, MBA, Vice President of Strategic Planning & Business Development, joined DURECT in 2016 and brings over 20 years of global commercial development, strategic planning, marketing and sales experience in the pharmaceuticals industry. Over his career, Mr. Janosky has been involved in over 10 product launches. In the past decade, Mr. Janosky led the commercial development, marketing and business analytics departments for several emerging pharmaceutical companies including Jazz Pharmaceuticals, Durect and Vivus. Mr. Janosky started his career in sales for Wyeth Laboratories and held management roles in market planning and marketing for Johnson & Johnson and ALZA Corporation. After obtaining his bachelors degree in biochemistry from the University of Vermont, Mr. Janosky conducted basic research at Massachusetts General Hospital before transitioning to industry. Mr. Janosky received his masters in finance and marketing from the Simon Business School at the University of Rochester.
Jian Li has served as our Vice President of Finance and Corporate Controller since December 2003.
Previously, Ms. Li served as our Corporate Controller from April 2001 to December 2003, Assistant Controller from December 2000 to April 2001 and our Accounting Manager from March 2000 to December 2000. Prior to joining DURECT, she held various positions at Elan Pharmaceuticals in California and GTE Hawaiian Telephone in Honolulu, Hawaii in the roles of Financial Analyst, Accountant and Marketing Analyst. Ms. Li holds an M.B.A. from the University of Hawaii at Manoa. She is also a Certified Public Accountant and a member of American Institute of Certified Public Accountants.
Dr. Miksztal has over 24 years of pharmaceutical product development experience. He joined DURECT in March 2000 as Senior Director of Pharmaceutical Development, and in October 2000 was promoted to Executive Director. Prior to joining DURECT, Dr. Miksztal was the Associate Director of the Pharmaceutical Analysis Department at Oread Laboratories from 1996 to 2000, a Senior Scientist in Pharmaceutical Research at Roche Bioscience from 1995 to 1996, and a Scientist in the Preformulation and Pharmaceutical Analysis Departments at Syntex Research from 1987 to 1995. Dr. Miksztal earned his Ph.D. degree in Chemistry from Rutgers University, and completed an NIH postdoctoral research fellowship in the Chemistry Department at the University of California, San Diego. He has numerous scientific publications and is the inventor of several U.S. and foreign patents.
Dr. Yum joined DURECT in 1999. Since then, he has continuously been involved in the application of several of DURECT's platform technologies such as DUROS, SABER and DURIN. Su IL's significant contributions have played a huge role in the development of various parenteral and oral drug delivery systems that are based on these DURECT technologies.
Prior to joining DURECT, Dr. Yum served as Senior Technical Advisor at Amira Medical in Scotts Valley, California, where he participated in the development of a pain-free blood glucose detector called AtLast.
Prior to joining Amira, he held a number of senior positions in project management and engineering at ALZA Corporation. His contributions at ALZA include the development of a number of ALZA's enabling technologies and commercial products, most notably transdermal patch products such as, Nicoderm nicotin and Duragesic fentanyl systems. Other products include; Travenol Infusor, which ALZA licensed to Baxter, and ALZET osmotic pumps, used for experimental research in laboratory animals. His fundamental insight into mass transport phenomena and product design were instrumental to his success in exploratory research, and development activities at ALZA.
Dr. Yum earned his Ph.D. degree in Chemical Engineering from the University of Minnesota, and completed post-doctoral research in Biomedical Engineering at the University of Utah. He has more than 40 scientific publications and is the holder of more than 60 U.S. and foreign patents. Dr. Yum is a Fellow of the AAPS.